智通财经APP获悉，特斯拉(TSLA.US)首席执行官马斯克周三在X平台上发表帖子强调称，相比诺和诺德(NVO.US)的减肥疗法Ozempic，他更偏好礼来(LLY.US)的竞品Mounjaro。
周三，马斯克发表了一篇题为“Ozempic Santa”的帖子以及他打扮成圣诞老人的图片。而在回答关于他使用的具体产品的问题时，马斯克指出：“从技术上讲，是Mounjaro，但这听起来不一样。”
“Mounjaro似乎副作用更小，更有效，”他解释道。
据了解，Mounjaro和Ozempic通用名分别为替尔泊肽和司美格鲁肽，属于一种胰高血糖素样肽1(GLP-1)受体激动剂，并分别以Zepbond和Wegovy的品牌名销售，用于减肥。
马斯克曾将他的减肥归功于Wegovy。不过，鉴于马斯克对GLP-1的坚定支持，他似乎与美国候任总统特朗普挑选的卫生部长小罗伯特·F·肯尼迪意见相左，后者长期以来一直主张控制饮食，而不是靠药物来对抗肥胖症。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.